

**INFORMATION ABOUT THE FACTS AND CIRCUMSTANCES OCCURRED
DURING THE FIRST QUARTER OF 2024
OF "SOPHARMA" AD**

Annex № 4

**To Art. 12, par. 1, it.1, art.14 of Ordinance № 2 from 09.11.2021
And Regulation (EU) 596/2014 of the European Parliament and of the Council
of 16 April 2014**

The persons who are liable for damages caused by false, misleading or incomplete data in this information as of 31.03.2024 are:

Ognyan Donev - Executive Director and Chairman of the Board of Directors of Sopharma AD

Vesela Stoeva – Deputy. - Chairman of the Board of Directors of Sopharma AD

Bisera Lazarova – Member of the Board of Directors of Sopharma AD

Alexander Chaushev – Member of the Board of Directors of Sopharma AD

Ivan Badinski - Member of the Board of Directors of Sopharma AD

1.1. No change in the persons controlling the Company.

1.2. No opening of bankruptcy proceedings against the company or its subsidiary or any significant events related to production.

1.3. No conclusion or execution of significant transactions.

1.4. No decision on conclusion, termination and cancellation of joint venture agreements.

1.5. Change of the auditors of the company - No change of auditors. At the Regular General Meeting of Shareholders of "SOPHARMA" AD, held on 2 June 2023, the auditing company "BAKER TILLY KLITOU AND PARTNERS" OOD, based in Sofia, Acad. "Ivan Evst. Geshov " 104, for a registered auditor for inspection and certification of the Annual Financial Statements of the Company.

1.6. There is no opening or termination of a court or arbitration case relating to the debts or claims of the company or its subsidiary with a claim price of at least 10% of the company's equity.

1.7. No purchases, sales or established pledges of shares in commercial companies by the issuer or its subsidiary.

1.8. The management believes that the military conflict between Russia and Ukraine could have a serious impact on the Company's activities, since the main part of product sales are realized in Ukraine and Russia.

The company has investments in two subsidiaries in Ukraine. As of the date of preparation of the financial statements, the assets of these subsidiaries are not physically affected by military action, but it is possible that in the future the value of these investments may need to be reviewed depending on the development of the war and its impact on the activities of the companies.

"Sopharma" AD informs all interested parties that the individual financial statements of the Company as at 31 March 2024 have not been verified by a registered auditor.

***This is a translation from Bulgarian of the Individual financial statements
of "Sopharma" AD.***

In case of divergence Bulgarian text should prevail.